Navigation Links
Encorium Group, Inc. Announces Terms of Proposed Rights Offering
Date:8/23/2010

cost effectively move products through the clinical development process.

This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the risk that we may not have sufficient funds to operate our business; (ii) our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; (xiii) uncertainties regarding the availability of additional capital; (xiv) uncertainties regarding the execution of change orders by our clients for work already performed; and (xv) uncertainties regarding continued listing of our common stock on Nasdaq. You should not place undue relia
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Encorium Reports Second Quarter 2010 Financial Results
2. Encorium Group, Inc. Acquires Progenitor International Research, a Vaccine Focused Emerging Market CRO
3. Encorium Re-Appoints Dr. Kai Lindevall as Chief Executive Officer and Appoints Current Director, Shahab Fatheazam, Chairman of the Board
4. Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors
5. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
6. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
7. Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials
8. Oxford Finance Corporation and United Orthopedic Group, Inc. Close $20 Million Credit Facility
9. Hanger Orthopedic Group, Inc. Announces Second Quarter 2010 Earnings Release Conference Call
10. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
11. Hanger Orthopedic Group, Inc. Announces Three Acquisitions With Annual Revenues of $14.0 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "12th ... and Production" report to their offering. ... of Biopharmaceutical Manufacturing Capacity and Production is the ... manufacturing organizations, current and projected future capacity and ...
(Date:8/28/2015)... Patterson Medical, formerly the medical business ... is now an independent company with today,s completion ... by Madison Dearborn Partners (MDP).  ... transition period before rebranding as the world,s leading ...  With the focused resources and expertise of MDP, ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Latanoprost Market, ... Developed by Pharmacia & Upjohn in 1995, latanoprost ... reduces intraocular pressure. As the first pressure- lowering ... name of Xalatan) entered China ...
Breaking Medicine Technology:12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3China Latanoprost Market Investigation Report 2015-2019 2
... Pharmaceutical,Inc.,s (OTC Bulletin Board: NURX) next-generation rexinoid agonist,NRX4204, ... tumors and,lowered the total tumor volume in mouse ... paper published in Clinical Cancer Research (2007;,Vol. 13, ... showed that NRX4204 caused marked tumor,regression in all ...
... provide best science available, BETHESDA, Md., March ... methodology for CNS clinical trials, United BioSource,Corporation (UBC) ... for,Data Quality. This Advisory Board was established to ... quality and outcomes in CNS trials that,rely on ...
Cached Medicine Technology:Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports 2Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports 3UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials 2UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials 3
(Date:8/31/2015)... Florida (PRWEB) , ... August 31, 2015 , ... ... is excited to establish its first Digital Hub in North America, now open ... before selecting Florida,” stated Founder and CEO John Campbell. “Jacksonville’s lifestyle, waterways and ...
(Date:8/31/2015)... ... August 31, 2015 , ... Intellitec Solutions announced they ... bringing on board their 8th new staff member in 2015. With the potential for ... firm. Intellitec Solutions supports Microsoft Dynamics GP, Dynamics SL, Dynamics CRM and Intacct, and ...
(Date:8/31/2015)... ... 31, 2015 , ... NSF International, an independent global organization ... sciences and consumer goods industries, has recognized Clean Water Systems & Stores Inc ... Manganese Dioxide. , Developed by a team of scientists and industry experts NSF/ANSI ...
(Date:8/31/2015)... ... August 31, 2015 , ... All birth control methods work best if ... failure rates among birth control methods. Moreover, no-scalpel vasectomy has many proven advantages with ... have their vasectomy done because they are afraid of complications. , One Stop ...
(Date:8/31/2015)... ... August 31, 2015 , ... Adult & Pediatric Dermatology in ... dermatology patients of the treatments and services available to help them. , ... innovative and ‘responsive design’ that allows visitors to view the website seamlessly on any ...
Breaking Medicine News(10 mins):Health News:Global Digital Opens USA Digital Agency Hub 2Health News:Intellitec Solutions Achieves Record Pace for New Hiring 2Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 2Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 3Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 3
... As ... be welcoming world leaders to the David L. Lawrence Convention Center, the largest "green" ... Design) certification. , ... Pittsburgh, Pa. (PRWEB) September 24, 2009 -- As the industry leader in automatic door ...
... , , , SEATTLE, ... launched the Living Proof Project: U.S. Investments in Global Health ... success of the U.S. government,s efforts to improve health around ... Project will show that U.S.-supported initiatives to fight malaria, AIDS, ...
... , , , INDIANAPOLIS, ... District of Indiana today upheld Eli Lilly and Company,s (NYSE: ... tablets). In the case of Eli Lilly and Company ... favor of Lilly on all accounts for these method-of-use patents, ...
... , , , ... Northern Ireland, moderated by President Clinton, featured Peter Robinson, first ... Northern Ireland Executive; Declan Kelly, economic envoy to Northern Ireland, ... Northern Ireland; and Micheal Martin, Minster of Foreign ...
... Sept. 23 Allowing age adjustments more restrictive than 5 to ... in the individual insurance market, making coverage unaffordable for many according ... Cross and Blue Shield Association (BCBSA) released today new data, prepared ... that a 2 to 1 age rating ratio would increase premiums ...
... NEW YORK, Sept. 23 The Michael J. ... to successfully translate neurotrophic factor advances from pre-clinical and early-phase ... The funding will be awarded under a new Directed ... , , The Foundation,s intention is to ...
Cached Medicine News:Health News:BEA Opens the Doors to the World at G20 Summit 2Health News:BEA Opens the Doors to the World at G20 Summit 3Health News:Gates Foundation Launches Campaign to Highlight Success of U.S. Global Health Investments 2Health News:Gates Foundation Launches Campaign to Highlight Success of U.S. Global Health Investments 3Health News:U.S. District Court Upholds Validity of Lilly's Evista Patents Through 2014 2Health News:U.S. District Court Upholds Validity of Lilly's Evista Patents Through 2014 3Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 2Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 3Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 4Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 5Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 6Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 7Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 8Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 9Health News:Analysis Shows Narrow Age Rating Would Raise Premiums by Nearly 50 Percent, Causing Many Young and Healthy to Forgo Coverage 2Health News:Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors 'From Promise to Reality' As Parkinson's Treatment 2
... this is the universal lithotripter for ... urinary and biliary treatment. The system ... with other applications including cystoscopy, ureteronoscopy, ... system comprises the height adjustable urologist' ...
... This therapeutic system ... the patient in mind. ... surgery and ongoing therapy, ... low-risk and effective therapy. ...
... Reach a new dimension! That of the ... unequalled performance and ease of use. Enjoy ... electroconductive shock wave technology coupled with the ... system. Manage the patient treatment, X-ray and ...
... The MINILITH SL1 developed by STORZ ... of extensive experience in the field of ... of the specific requirements to be met ... therapy, as has been outlined above. The ...
Medicine Products: